Shares of Gland Pharma were up 2.02% in Wednesday's session, with the stock trading at Rs 1,934.10. The stock movement is tracked against its previous close.
Financial Snapshot:
Here's a look at Gland Pharma's key financial data:
| Heading | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Revenue | Rs 1,537.45 Crore | Rs 1,401.71 Crore | Rs 1,405.83 Crore | Rs 1,384.05 Crore | Rs 1,424.91 Crore |
| Net Profit | Rs 192.42 Crore | Rs 143.76 Crore | Rs 163.53 Crore | Rs 204.69 Crore | Rs 186.54 Crore |
| EPS | 11.68 | 8.73 | 9.93 | 12.42 | 11.32 |
The company's quarterly revenue saw fluctuations, with a slight decrease from Rs 1,537.45 Crore in March 2024 to Rs 1,424.91 Crore in March 2025. Similarly, the net profit also experienced variations, ending at Rs 186.54 Crore in the quarter-ending March 2025.
Annual Performance:
| Heading | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | Rs 3,462.88 Crore | Rs 4,400.71 Crore | Rs 3,624.60 Crore | Rs 5,664.72 Crore | Rs 5,616.50 Crore |
| Net Profit | Rs 996.96 Crore | Rs 1,211.66 Crore | Rs 781.04 Crore | Rs 772.46 Crore | Rs 698.53 Crore |
| EPS | 63.07 | 73.81 | 47.44 | 46.90 | 42.40 |
| BVPS | 360.86 | 435.64 | 483.23 | 529.65 | 555.40 |
| ROE | 16.88 | 16.92 | 9.81 | 8.85 | 7.63 |
| Debt to Equity | 0.00 | 0.00 | 0.00 | 0.04 | 0.03 |
The annual revenue for Gland Pharma has shown an increase from Rs 3,462.88 Crore in 2021 to Rs 5,616.50 Crore in 2025. However, the net profit decreased from Rs 996.96 Crore in 2021 to Rs 698.53 Crore in 2025. The debt-to-equity ratio has remained relatively low, standing at 0.03 in 2025.
Standalone Income Statement (Annual):
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Sales | Rs 4,116 Crore | Rs 4,167 Crore | Rs 3,616 Crore | Rs 4,400 Crore | Rs 3,462 Crore |
| Other Income | Rs 215 Crore | Rs 166 Crore | Rs 240 Crore | Rs 223 Crore | Rs 134 Crore |
| Total Income | Rs 4,331 Crore | Rs 4,334 Crore | Rs 3,856 Crore | Rs 4,624 Crore | Rs 3,597 Crore |
| Total Expenditure | Rs 2,842 Crore | Rs 2,920 Crore | Rs 2,801 Crore | Rs 3,000 Crore | Rs 2,259 Crore |
| EBIT | Rs 1,488 Crore | Rs 1,413 Crore | Rs 1,055 Crore | Rs 1,624 Crore | Rs 1,338 Crore |
| Interest | Rs 22 Crore | Rs 7 Crore | Rs 7 Crore | Rs 5 Crore | Rs 3 Crore |
| Tax | Rs 375 Crore | Rs 362 Crore | Rs 272 Crore | Rs 406 Crore | Rs 337 Crore |
| Net Profit | Rs 1,089 Crore | Rs 1,043 Crore | Rs 775 Crore | Rs 1,212 Crore | Rs 997 Crore |
The standalone annual sales for Gland Pharma decreased from Rs 4,167 Crore in March 2024 to Rs 4,116 Crore in March 2025. The net profit increased from Rs 1,043 Crore in March 2024 to Rs 1,089 Crore in March 2025.
Standalone Income Statement (Quarterly):
| Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | |
|---|---|---|---|---|---|
| Sales | Rs 1,030 Crore | Rs 1,010 Crore | Rs 1,062 Crore | Rs 1,012 Crore | Rs 1,174 Crore |
| Other Income | Rs 43 Crore | Rs 65 Crore | Rs 57 Crore | Rs 48 Crore | Rs 46 Crore |
| Total Income | Rs 1,074 Crore | Rs 1,075 Crore | Rs 1,120 Crore | Rs 1,060 Crore | Rs 1,221 Crore |
| Total Expenditure | Rs 679 Crore | Rs 663 Crore | Rs 740 Crore | Rs 759 Crore | Rs 784 Crore |
| EBIT | Rs 394 Crore | Rs 412 Crore | Rs 379 Crore | Rs 301 Crore | Rs 437 Crore |
| Interest | Rs 3 Crore | Rs 18 Crore | Rs 0 Crore | Rs 0 Crore | Rs 4 Crore |
| Tax | Rs 101 Crore | Rs 99 Crore | Rs 98 Crore | Rs 77 Crore | Rs 111 Crore |
| Net Profit | Rs 290 Crore | Rs 295 Crore | Rs 281 Crore | Rs 222 Crore | Rs 321 Crore |
The standalone quarterly sales for Gland Pharma decreased from Rs 1,174 Crore in March 2024 to Rs 1,030 Crore in March 2025. The net profit decreased from Rs 321 Crore in March 2024 to Rs 290 Crore in March 2025.
Cash Flow:
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Operating Activities | Rs 1,073 Crore | Rs 1,135 Crore | Rs 367 Crore | Rs 791 Crore | Rs 604 Crore |
| Investing Activities | Rs 1,578 Crore | Rs -2,923 Crore | Rs 1,208 Crore | Rs -1,010 Crore | Rs -1,524 Crore |
| Financing Activities | Rs -339 Crore | Rs -7 Crore | Rs 14 Crore | Rs 34 Crore | Rs 1,238 Crore |
| Others | Rs 4 Crore | Rs 6 Crore | Rs 3 Crore | Rs 3 Crore | Rs 3 Crore |
| Net Cash Flow | Rs 2,316 Crore | Rs -1,789 Crore | Rs 1,594 Crore | Rs -180 Crore | Rs 322 Crore |
Gland Pharma's cash flow from operating activities was Rs 1,073 Crore in March 2025, compared to Rs 1,135 Crore in the previous year. The net cash flow stood at Rs 2,316 Crore in March 2025.
Balance Sheet:
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Share Capital | Rs 16 Crore | Rs 16 Crore | Rs 16 Crore | Rs 16 Crore | Rs 16 Crore |
| Reserves & Surplus | Rs 9,738 Crore | Rs 8,977 Crore | Rs 7,935 Crore | Rs 7,141 Crore | Rs 5,886 Crore |
| Current Liabilities | Rs 523 Crore | Rs 414 Crore | Rs 730 Crore | Rs 581 Crore | Rs 512 Crore |
| Other Liabilities | Rs 142 Crore | Rs 132 Crore | Rs 91 Crore | Rs 94 Crore | Rs 80 Crore |
| Total Liabilities | Rs 10,421 Crore | Rs 9,541 Crore | Rs 8,773 Crore | Rs 7,834 Crore | Rs 6,496 Crore |
| Fixed Assets | Rs 1,784 Crore | Rs 1,813 Crore | Rs 1,747 Crore | Rs 1,692 Crore | Rs 1,292 Crore |
| Current Assets | Rs 5,766 Crore | Rs 4,571 Crore | Rs 6,888 Crore | Rs 5,844 Crore | Rs 5,123 Crore |
| Other Assets | Rs 2,870 Crore | Rs 3,156 Crore | Rs 137 Crore | Rs 296 Crore | Rs 80 Crore |
| Total Assets | Rs 10,421 Crore | Rs 9,541 Crore | Rs 8,773 Crore | Rs 7,834 Crore | Rs 6,496 Crore |
| Contingent Liabilities | Rs 0 Crore | Rs 100 Crore | Rs 128 Crore | Rs 124 Crore | Rs 219 Crore |
Gland Pharma's total assets stood at Rs 10,421 Crore in March 2025, with current assets at Rs 5,766 Crore. The reserves and surplus increased to Rs 9,738 Crore.
Ratios:
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Basic EPS (Rs.) | 66.15 | 63.35 | 47.12 | 73.84 | 63.07 |
| Diluted Eps (Rs.) | 66.15 | 63.35 | 47.11 | 73.67 | 62.99 |
| Book Value /Share (Rs.) | 592.08 | 546.13 | 482.90 | 435.68 | 360.86 |
| Dividend/Share (Rs.) | 18.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Face Value | 1 | 1 | 1 | 1 | 1 |
| Gross Profit Margin (%) | 40.27 | 37.80 | 34.81 | 39.41 | 41.49 |
| Operating Margin (%) | 36.16 | 33.91 | 30.75 | 36.90 | 38.64 |
| Net Profit Margin (%) | 26.47 | 25.03 | 21.45 | 27.54 | 28.79 |
| Return on Equity (%) | 11.17 | 11.59 | 9.75 | 16.93 | 16.88 |
| ROCE (%) | 15.03 | 15.48 | 13.82 | 22.39 | 22.36 |
| Return On Assets (%) | 10.45 | 10.93 | 8.84 | 15.47 | 15.34 |
| Current Ratio (X) | 11.01 | 11.04 | 9.43 | 10.04 | 10.00 |
| Quick Ratio (X) | 8.62 | 7.99 | 6.77 | 8.01 | 7.51 |
| Debt to Equity (x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratios (X) | 72.59 | 200.87 | 169.82 | 331.03 | 392.34 |
| Asset Turnover Ratio (%) | 0.41 | 0.46 | 0.44 | 0.61 | 53.30 |
| Inventory Turnover Ratio (X) | 1.26 | 1.14 | 1.10 | 1.66 | 2.72 |
| 3 Yr CAGR Sales (%) | -3.29 | 9.70 | 17.19 | 46.72 | 46.21 |
| 3 Yr CAGR Net Profit (%) | -5.18 | 2.30 | 0.19 | 63.78 | 76.21 |
| P/E (x) | 24.07 | 29.13 | 26.92 | 44.32 | 39.29 |
| P/B (x) | 2.69 | 3.37 | 2.63 | 7.50 | 6.87 |
| EV/EBITDA (x) | 14.36 | 18.24 | 13.61 | 29.19 | 26.12 |
| P/S (x) | 6.37 | 7.28 | 5.78 | 12.21 | 11.71 |
Gland Pharma’s dividend per share stood at Rs 18.00 in March 2025. The price-to-earnings ratio was 24.07, and the price-to-book ratio was 2.69 as of March 2025.
Gland Pharma is included as one of the stocks in the benchmark NIFTY MIDCAP 150 index. According to Moneycontrol analysis, the sentiment is very bullish for the stock.
The company announced a final dividend of Rs 18 per share (1800%) on May 20, 2025.
With the stock currently trading at Rs 1,934.10, Gland Pharma has demonstrated a positive movement in today's session.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
